Karyopharm Therapeutics (KPTI) EBITDA Margin (QoQ) (2013 - 2025)
Powered by 
Analysis
Karyopharm Therapeutics (KPTI) EBITDA Margin (QoQ) (2013 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.34 Bn | 621.58 Bn | 17.26 Bn |
| 2 | AbbVie | 446.74 Bn | 440.17 Bn | 12.70 Bn |
| 3 | Merck | 357.89 Bn | 350.75 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.44 Bn | 259.75 Bn | 11.24 Bn |
| 5 | Pfizer | 156.55 Bn | 144.85 Bn | 10.94 Bn |
| 6 | Sanofi | 52.21 Bn | 44.83 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.85 Bn | 42.85 Bn | - |
| 8 | Incyte | 24.63 Bn | 20.09 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.40 Bn | 18.74 Bn | 683.80 Mn |
| 10 | Karyopharm Therapeutics | 46.32 Mn | -18.78 Mn | 32.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -1,780.00 |
| Sep 30, 2025 | 2,974.00 |
| Jun 30, 2025 | 4,650.00 |
| Mar 31, 2025 | -838.00 |
| Dec 31, 2024 | -3,465.00 |
| Sep 30, 2024 | -205.00 |
| Jun 30, 2024 | 3,619.00 |
| Mar 31, 2024 | 1,012.00 |
| Dec 31, 2023 | -2,522.00 |
| Sep 30, 2023 | -812.00 |
| Jun 30, 2023 | 115.00 |
| Mar 31, 2023 | 2,101.00 |
| Dec 31, 2022 | -1,554.00 |
| Sep 30, 2022 | 2,282.00 |
| Jun 30, 2022 | -3,558.00 |
| Mar 31, 2022 | -10,974.00 |
| Dec 31, 2021 | 15,344.00 |
| Sep 30, 2021 | 10,077.00 |
| Jun 30, 2021 | 815.00 |
| Mar 31, 2021 | -11,956.00 |